MENU
+Compare
HYPMY
Stock ticker: OTC
AS OF
Feb 21 closing price
Price
$3.40
Change
-$0.05 (-1.45%)
Capitalization
5.79B

HYPMY stock forecast, quote, news & analysis

HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for HYPMY with price predictions
Feb 07, 2025

HYPMY in -3.65% downward trend, declining for three consecutive days on January 29, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HYPMY declined for three days, in of 278 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where HYPMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

HYPMY broke above its upper Bollinger Band on February 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 31, 2025. You may want to consider a long position or call options on HYPMY as a result. In of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

HYPMY moved above its 50-day moving average on January 30, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HYPMY crossed bullishly above the 50-day moving average on January 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPMY advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 200 cases where HYPMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.476) is normal, around the industry mean (59.993). P/E Ratio (15.949) is within average values for comparable stocks, (90.174). HYPMY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.026) settles around the average of (0.122) among similar stocks. P/S Ratio (3.452) is also within normal values, averaging (19.928).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HYPMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Dividends

HYPMY paid dividends on January 12, 2023

Hypera SA HYPMY Stock Dividends
А dividend of $0.06 per share was paid with a record date of January 12, 2023, and an ex-dividend date of December 29, 2022. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.61B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was 77%, and the average quarterly price growth was 50%. ECGS experienced the highest price growth at 99%, while PTPI experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 165%. For the same stocks of the Industry, the average monthly volume growth was 322% and the average quarterly volume growth was 662%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 68
Price Growth Rating: 63
SMR Rating: 83
Profit Risk Rating: 90
Seasonality Score: -43 (-100 ... +100)
View a ticker or compare two or three
HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
Avenida Magalhaes de Castro, 4800
Phone
N/A
Employees
7515
Web
https://www.hypermarcas.com.br